Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This case report presents a patient with idiopathic isolated ACTH deficiency and testicular germ cell tumor, with alopecia areata as an initial symptom, suggesting a potential link between these conditions.

In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

In this study, researchers found that simple hair clipping in mice induced dynamic plasticity and axogenesis in skin sensory axons, linked to follicular activation and HGF signaling.

In this report, an 18-year-old female with trichotillomania was successfully treated using the glutamate modulator n-acetylcysteine.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4^CRBN as the E3 ligase.

The authors concluded that some patients clinically diagnosed with telogen effluvium may actually have alopecia areata incognita, suggested by the presence of dystrophic hairs and development of alopecia patches.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

In this study, the researchers observed that subjects with alopecia areata had the highest plasma level of cardiac troponin I, followed by those with androgenetic alopecia, and the lowest levels in individuals without hair loss.

This study from the Danish Skin Cohort found that patients with alopecia areata, followed by those with hidradenitis suppurativa, were willing to spend the most daily time on treatment, reflecting possible unmet needs, and that this willingness correlated with disease severity across different dermatological conditions.

In this study, novel mutations in the BTD gene were identified in a patient with profound biotinidase deficiency, highlighting the importance of biotinidase activity measurement and mutation analysis for early diagnosis.

This study observed that extracellular ATP (eATP) levels outside Arabidopsis root cells vary inversely with the expression of AtAPY1 and AtAPY2 apyrases, suggesting these enzymes regulate eATP concentrations crucial for root growth.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study found that terminally differentiated effector memory Vδ1T-cells and their cytotoxic activation markers were elevated in alopecia areata patients, suggesting these cells may contribute to its early pathogenesis.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.